We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Use of Molecular Assays for HIAs Growing Rapidly

By LabMedica International staff writers
Posted on 07 Oct 2010
Molecular tests that can quickly identify hospital- acquired infections (HIAs) are rapidly becoming more popular.

The most serious HAIs include methicillin resistant Staphylococcus aureus (MRSA), Clostridium difficile, which causes an intestinal infection), Vancomycin-resistant Enterococcus, linked with intestinal, skin and blood infections, and drug-resistant Acinetobacter, which can cause pneumonia, skin, and blood infections.

Image: A conceptual visualization of the methicillin-resistant staphylococcus aureus (MRSA) bacteria (photo courtesy Medical RF.com).
Image: A conceptual visualization of the methicillin-resistant staphylococcus aureus (MRSA) bacteria (photo courtesy Medical RF.com).

There are several approaches to HAI detection. On the conservative and least expensive side are chromogenic growth media that permit the selective growth of MRSA bacteria and produce a colored colony that is easily recognizable. On the more expensive side, there has been an explosion of user-friendly molecular assays that are widely accepted.

Kalorama Information (Rockville, MD, USA), a healthcare market research publisher, has reported that molecular tests that can quickly identify patients for isolation and treatment are being utilized despite their higher cost. Kalorama forecasts that revenues for molecular tests that detect HAIs will grow at 25% per year for the next five years.

"They are growing at four times the rate of the average IVD products,” said Shara Rosen, senior diagnostic analyst for Kalorama Information and the author of the report. "HAIs are a huge problem and this is an opportunity for the most logical tests to treat them.”

The advantage of these molecular tests is that they can provide highly sensitive rapid turnaround results. Cepheid (Sunnyvale, CA, USA), Becton Dickinson (BD; Franklin Lakes, CA, USA), and Seegene (Seoul, Korea) are among the companies with products used to test for HAIs.

The US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) estimates that HAIs affect nearly 2 million Americans annually, resulting in 90,000 deaths and up to US $6.5 billion in extra costs.

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services.

Related Links:
Cepheid
Becton Dickinson
Seegene
Kalorama Information
U.S. Centers for Disease Control and Prevention



Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Automated Blood Typing System
IH-500 NEXT
New
Newborn Screening Test
NeoMass AAAC 3.0
New
Automatic Biochemistry Analyzer
Audmax 180 Evolution

Latest Industry News

Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

Microbiologics Acquires Diagnostic Quality Controls Manufacturer SensID

Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests